Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PreCision Dermatology Inc.

Division of Valeant Pharmaceuticals International Inc.
www.precisionderm.com

Latest From PreCision Dermatology Inc.

Finance Watch: A Bountiful November Harvest For Venture-Backed Biopharma

Five funds raised more than $1bn to back biotech firms; Arcus leads recent VC rounds with $107m GV-backed Series C; Celgene, Valeant sell notes to retire debt; and Alnylam cashes in on investor goodwill.

Financing Business Strategies

Deal Watch: Allergan Makes Another Defensive Play Against Valeant Takeover

In a pair of diabetes-related transaction, Sanofi pays $175 million upfront to MannKind for worldwide license to inhaled insulin Afrezza, while Janssen options Phase I stem cell program from ViaCyte. Novartis gets purchase option for stem-cell biotech Gamida Cell and MorphoSys in-licenses a preclinical prostate cancer antibody candidate from Emergent BioSolutions.

BioPharmaceutical Deals

Deals Shaping The Medical Industry, June 2014

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced April through May 2014.

BioPharmaceutical Consumer

Start-Up Quarterly Statistics, Q1 2014

Start-up companies raised $1.18 billion during the first quarter of 2014, up $2.8 million from last quarter’s total. Cancer was the leading therapy area involved in alliances.

BioPharmaceutical Medical Device
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register